Vaginal atrophy is the thinning and drying of the vaginal walls as a result of the natural drop in the levels of oestrogen in your body after the menopause. Common symptoms include vaginal dryness and irritation, dyspareunia (recurring pain during sexual intercourse) and increased urination frequency, urgency, incontinence, or burning. Up to 50% of postmenopausal women have at least some degree of vaginal atrophy. Vaginal atrophy most often happens in late postmenopause. In more severe cases, women may have discomfort sitting, exercising, or wearing tight fitting clothing.
Vagirux is inserted as a tablet into your vagina, so the hormone is released locally, where it is needed. The tablets adhere to the vaginal wall and release the oestrogen in a controlled way through the hydrated gel layer it forms. This replacement oestrogen can reduce irritation by keeping the vagina moist, elastic and acidic. As Vagirux is inserted directly into the vagina and so works locally, it has a lower risk of side-effects compared with other systemic HRT treatments that work throughout the body (e.g. those taken orally or as patches, gels or spray).
The single multi-use applicator can be disposed via household waste and is recyclable.
For additional information, you should also read the instructional leaflet that is in your pack (patient information leaflet, PIL) and the “What do I need to know about Vagirux®?” leaflet that you should have received from your doctor, pharmacist or nurse. Please remember that if you have any questions, or you experience any side effects, including ones not listed in the Vagirux PIL, speak to your doctor, nurse or pharmacist.
In the UK, you can report side effects by going to www.mhra.gov.uk/yellowcard.
By reporting side effects, you can help provide more information about the safety of Vagirux.